Cite

    Sacré, A. et al. (2016). Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor. Acta oncologica. pp. 329-340. [Online].